MedTrace Logo

WS®1442 in Slightly Overweight Subjects

NCT00982501 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-05-14

No results posted yet for this study

Summary

The purpose of this study is to test:

1. Safety of 900 mg or 1800 mg of WS® 1442 per day in overweight subjects (BMI 25 to 29,9 kg/m²)
2. Pharmacodynamic effect of WS® 1442 on endothelial function versus nordic walking training in overweight subjects

Conditions

Interventions

DRUG

WS® 1442 900 mg/d

DRUG

WS® 1442 1800 mg/d

BEHAVIORAL

Nordic walking training 2 x 30 min/week

BEHAVIORAL

Nordic walking training 4x45 min/week

Sponsors & Collaborators

  • Dr. Willmar Schwabe GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Josef Niebauer, M.D., Ph.D. · University Institute of Sports Medicine, Prevention and Rehabilitation

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-09-30
Completion
2011-02-28

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982501 on ClinicalTrials.gov